Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized medicine in major depressive disorder -- opportunities and pitfalls.

Metabolism: clinical and experimental - 1 Jan 2013

Miller Diane B, O'Callaghan James P

Abstract excerpt

The sequencing of the human genome in the early days of this millennium was greeted with great fanfare as this accomplishment was expected to revolutionize medicine and result in individualized treatments based on the genetic make-up of the patient. The ultimate promise of personalized medicine would be fulfilled with the identification of disease biomarkers that would be widely available for use in diagnosis and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Depressive Disorder, Major
Share to Hypothalamo-Hypophyseal System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Nerve Growth Factors

Share to Neurotransmitter Agents

Share to Primary Health Care

Share to United States Food and Drug Administration

Source

Open in PubMed Open full text

Identifiers

PMID: 23021040
DOI: 10.1016/j.metabol.2012.08.021
PMCID: PMC4672728

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized medicine in major depressive disorder -- opportunities and pitfalls.PMID 23021040Read ↗

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment.Semantic proximity Read ↗

Advances in biomarkers of major depressive disorder.Semantic proximity Read ↗

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant responseSemantic proximity Read ↗

Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.Semantic proximity Read ↗

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depressive disorderSemantic proximity Read ↗

Pharmacogenetic studies: a tool to improve antidepressant therapy.Semantic proximity Read ↗

The pharmacogenetics of major depression: past, present, and future.Semantic proximity Read ↗

Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Genetic variants in major depressive disorder: From pathophysiology to therapy.Semantic proximity Read ↗

Personalized medicine in psychiatry: problems and promises.Semantic proximity Read ↗

Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Semantic proximity Read ↗

Depression and Pharmacogenetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.